Sign Up to like & get
recommendations!
0
Published in 2021 at "Contemporary Clinical Trials Communications"
DOI: 10.1016/j.conctc.2021.100753
Abstract: We introduce a Bayesian optimization method for estimating the maximum tolerated dose in this article. A number of parametric model-based methods have been proposed to estimate the maximum tolerated dose; however, parametric model-based methods need…
read more here.
Keywords:
tolerated dose;
bayesian optimization;
method;
maximum tolerated ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0735-y
Abstract: Rambaldi, A., Iurlo, A., Vannucchi, A. M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M. F., Cambier, N., Marolleau, J-P., Mesa, R. A.,…
read more here.
Keywords:
efficacy maximum;
tolerated dose;
safety efficacy;
givinostat polycythemia ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical trials"
DOI: 10.1177/17407745231160092
Abstract: Background: The use of ‘backfilling’, assigning additional patients to doses deemed safe, in phase I dose-escalation studies has been used in practice to collect additional information on the safety profile, pharmacokinetics and activity of a…
read more here.
Keywords:
escalation studies;
dose escalation;
phase;
phase dose ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.810848
Abstract: Purpose To compare the clinical outcomes of maximum tolerated medical therapy (MTMT) in patients with penetrating keratoplasty (PKP) with those of Ahmed glaucoma valve (AGV) implantation. Methods The medical records were retrospectively reviewed in patients…
read more here.
Keywords:
tolerated medical;
bullous keratopathy;
group;
penetrating keratoplasty ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01416
Abstract: The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been…
read more here.
Keywords:
combination;
treatment;
maximum tolerated;
ewing sarcoma ... See more keywords